Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed Inc. (INSM) Form 4 filing discloses two open-market sales by Chief Legal Officer Michael A. Smith.
- 07/11/2025: 748 common shares sold at $96.41 to satisfy tax-withholding on RSU vesting.
- 07/15/2025: 933 common shares sold at a $102.51 weighted-average price under a pre-arranged Rule 10b5-1 trading plan adopted 02/27/2025.
- Total shares disposed: 1,681, representing roughly 2.5 % of his pre-sale direct holdings.
- Post-sale direct ownership: 66,394 shares, including 357 acquired via the 2018 ESPP.
No derivative transactions were reported. Sales appear routine and transparent, suggesting limited immediate valuation impact for investors.
Insider Trading Activity Report: Sara Bonstein, Chief Financial Officer of Insmed, executed significant transactions on June 23, 2025, through a pre-planned 10b5-1 trading plan established on March 5, 2025.
Transaction Details:
- Exercised 35,253 stock options at $18.95 per share and 12,636 options at $19.74 per share
- Sold 49,104 shares at weighted average price of $101.71 (range: $101.04-$102.03)
- Sold additional 8,661 shares at weighted average price of $102.15 (range: $102.04-$102.61)
Following these transactions, Bonstein holds 93,536 shares directly, plus remaining stock options including 99,007 at $18.95 strike price and 25,124 at $19.74 strike price. The options vest over four years with 25% vesting on first anniversary and 12.5% every six months thereafter.
Form 144 Notice of Proposed Sale filed by Sara Bonstein of Insmed indicates planned sale of 57,765 shares of common stock with an aggregate market value of $5,877,434 through Merrill Lynch. The sale is scheduled for June 23, 2025, on NASDAQ.
The shares were acquired through multiple stock plan activities between May 2024 and June 2025, with the largest acquisition being 47,889 shares on June 23, 2025. The filing reveals significant recent selling activity by Bonstein in the past 3 months:
- June 10, 2025: 57,766 shares sold for $5,146,210
- May 13-14, 2025: Combined 10,504 shares sold for $708,680
- June 3, 2025: 1,579 shares sold for $112,898
Total shares outstanding: 182,138,923. This planned sale represents approximately 0.03% of total shares outstanding.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
